BridgeBio Pharma’s Pipeline Expansion Continues As Existing Portfolio’s Milestones Approach

The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.

white pills with bottle on blue background. genetic diseases concept — BridgeBio's genetic disease drug candidates span small molecules, biologics and gene therapies • Source: Shutterstock

BridgeBio Pharma Inc. is poised to achieve its goal of rapidly bringing treatments for genetic diseases and genetically defined cancers to the market with two different products expected to be submitted to the US Food and Drug Administration before the end of 2021 – just four years after the company’s first big funding round.

Palo Alto, CA-based BridgeBio recently raised $463.7m in net proceeds from the sale of 2.5% convertible senior notes due in...